Patient-reported satisfaction with telemedicine in light chain (AL) amyloidosis care

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors gratefully acknowledge the contribution of all participants and the Amyloidosis Support Groups, Inc. in this study. Research reported in this publication was supported by K23 HL141445, the Research and Education Program of Advancing Healthier Wisconsin and the Clinical and Translational Science Institute (CTSI) (KL2 TR001438). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

IA created and maintained the dataset, assisted in data cleanup, conducted analysis, and wrote the first draft of the paper; KEF designed the survey, reviewed the analysis, and edited the manuscript; MF contributed to the study design and assisted with survey dissemination; AS maintained the dataset, conducted data cleanup, and conducted analysis, AD designed the study, obtained funding, reviewed the analysis, and co-wrote the manuscript. All authors reviewed and approved the final draft.

Disclosure statement

No potential conflict of interest was reported by the author(s). KEF reports institutional research funding from Novartis, Consulting fees from Inhibikase and Pfizer. AD reports institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, and TeneoBio, advisory board and consulting fees from BMS, Pfizer, Prothena, and Janssen. The authors confirm no competing financial interests in relation to the work in this manuscript.

Additional information

Funding

This work was supported by National Heart, Lung, and Blood Institute grant K23HL141445 (AD).